Categories AlphaGraphs, Earnings, Health Care

Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook

Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also exceeded Wall Street’s projection amid a 29% growth in revenues. The management has raised its full-year outlook for product revenue, citing the continued expansion of the company’s cystic fibrosis drug pipeline.

Third-quarter earnings, on an adjusted basis, rose sharply to $3.56 per share from $2.64 per share in the corresponding period of last year. The number also came in above analysts’ forecast. Unadjusted net income was $851.9 million or $3.28 per share, compared to $667.4 million or $2.53 per share in the third quarter of 2020.

Vertex Pharmaceuticals Q3 2021 earnings infographic

The impressive earnings performance reflects a 29% increase in revenues to $1.98 billion. Market watchers were looking for slower growth. The top-line benefitted from the continued expansion of the company’s pipeline in cystic fibrosis and incremental investment to support the launches of medicines globally.

“Our financial performance in the third quarter was outstanding, marked by the exceptional continued growth of TRIKAFTA/KAFTRIO. Based on these results, we are again raising our 2021 product revenue guidance, and we see significant additional growth ahead as we continue to deliver this transformational medicine to more people with CF,” said Reshma Kewalramani, CEO of Vertex.


Read management/analysts’ comments on quarterly results


VRTX’s shares have made strong gains after the recent earnings announcement but lost momentum since then. In the past twelve months, the stock has lost about 42%.

Prior Performance

  • Vertex Pharma Q1 2021 earnings
  • Vertex Pharmaceuticals Q3 2019 Earnings Infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Hormel Foods (HRL) fine-tunes biz strategy to beat challenges. Is the stock a buy?

For consumer staples companies, rising inflation is probably turning into a bigger challenge than the virus-induced supply chain disruption and store closures. After bettering its position since the early months

HP Inc. (HPQ) stock research summary | Q3 2021

HP Inc has shown a strong performance in Q4 2021. In spite of remote working, HP has shown a strong demand for PC and printer. The company has beat Zacks

VMware Inc. (VMW) stock research summary | Q3 2021

In this era of digital transformation, the technology industry is seeing a rapid influx of innovative products and solutions that help businesses adapt to the fast-changing and complex environment. VMware

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top